JACKSONVILLE, Fla. - Johnson & Johnson (NYSE:JNJ) announced today the expanded U.S. availability of its TECNIS PureSee intraocular lens, a presbyopia-correcting lens for cataract surgery patients.
The TECNIS PureSee IOL is an extended depth of focus lens designed to provide distance and intermediate vision with some near vision for patients undergoing cataract surgery, according to a company press release. The lens addresses both cataract-related vision loss and presbyopia, a condition affecting nearly everyone by age 50 that reduces the ability to see objects clearly up close.
More than 500,000 eyes worldwide have been implanted with the TECNIS PureSee IOL. In clinical studies, 97% of patients reported no very bothersome visual disturbances and would recommend the lens to friends or family.
The lens is the first FDA-approved extended depth of focus intraocular lens with no warning on loss of contrast sensitivity, which refers to a patient’s ability to distinguish an object from its background in low-light or foggy conditions.
"With the full U.S. availability of TECNIS PureSee IOL, we are expanding access to an important extended depth of focus option," said Erin Powers, President of Surgical Vision, North America at Johnson & Johnson.
Nearly 20% of Americans aged 40 and older live with cataracts, though only 5% have undergone cataract surgery, according to Centers for Disease Control and Prevention data cited in the release. Cataract surgery has a success rate of nearly 98%.
The company is launching a patient lifestyle quiz during Cataract Awareness Month to help individuals assess their vision needs before surgery. The quiz is designed to facilitate discussions between patients and eye care professionals about which TECNIS lens option may be appropriate.According to InvestingPro analysis, JNJ currently trades below its Fair Value, suggesting potential upside for investors. The company maintains a "GREAT" financial health score and has raised its dividend for 55 consecutive years. For deeper insights into JNJ’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.
The TECNIS PureSee IOL is indicated for adult patients with less than 1 diopter of pre-existing corneal astigmatism. A toric version is available for patients with greater astigmatism levels.
In other recent news, Johnson & Johnson announced the successful results of its Phase 2/3 ENERGY study, where its drug Imaavy achieved a significant durable hemoglobin response in patients with warm autoimmune hemolytic anemia. Meanwhile, a Los Angeles jury awarded $32 million to the family of a woman who died from mesothelioma, finding Johnson & Johnson liable due to asbestos-contaminated talc in its baby powder. In a strategic move, Johnson & Johnson entered into an agreement to acquire Firefly Bio for $1 billion, aiming to leverage Firefly’s innovative degrader antibody conjugate platform. Additionally, the company’s nipocalimab met the primary endpoint in the Phase 2 JASMINE study for systemic lupus erythematosus, showing promising results in reducing disease activity. Johnson & Johnson also reported positive outcomes from its Phase 3 PROTEUS study, where apalutamide, combined with hormone therapy, reduced the risk of metastasis or death by 20% in prostate cancer patients. These developments reflect Johnson & Johnson’s ongoing efforts in advancing treatment options across various medical conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for JNJ plus thousands of other stocks and find your next hidden gem with massive upside.